GENCOR INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GENCOR INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Sep 30, 2013 | $48.94M | Dec 13, 2013 |
| FY2012 | Sep 30, 2012 | $63.18M | Dec 14, 2012 |
| FY2012 | Sep 30, 2011 | $59.69M | Dec 14, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Sep 30, 2012 | $13.99M | Dec 14, 2012 |
| FY2012 | Jun 30, 2012 | $22.99M | Dec 14, 2012 |
| FY2012 | Mar 31, 2012 | $19.34M | Dec 14, 2012 |
| FY2012 | Dec 31, 2011 | $6.86M | Dec 14, 2012 |
| FY2012 | Sep 30, 2011 | $12.17M | Dec 14, 2012 |
| FY2012 | Jun 30, 2011 | $23.02M | Dec 14, 2012 |
| FY2012 | Mar 31, 2011 | $16.73M | Dec 14, 2012 |
| FY2012 | Dec 31, 2010 | $7.79M | Dec 14, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $31.71M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $31.33M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $29.04M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $20.54M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $18.18M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $18.95M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $22.41M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $26.80M | Dec 11, 2019 |
| FY2017 | Sep 30, 2017 | $3.66M | Dec 6, 2017 |
| FY2017 | Jun 30, 2017 | $6.69M | Dec 6, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $15.66M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $14.56M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $14.67M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | ($372.0K) | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $5.81M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $5.53M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $10.20M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $12.69M | Dec 11, 2019 |
| FY2017 | Sep 30, 2017 | $1.02M | Dec 6, 2017 |
| FY2017 | Jun 30, 2017 | $2.59M | Dec 6, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $14.02M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $13.69M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $13.43M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $4.17M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $701.0K | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $5.54M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $9.47M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $13.89M | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $10.24M | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $7.82M | Dec 6, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.76M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $3.31M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $3.46M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $4.33M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $4.28M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $3.06M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $3.30M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $2.92M | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $2.15M | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $1.57M | Dec 6, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $14.94M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $14.33M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $12.15M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $12.05M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $13.20M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $10.36M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $9.65M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $9.99M | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $8.78M | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $8.14M | Dec 6, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.07M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $9.29M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $10.20M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | ($9.14M) | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $3.82M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $26.77M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $4.16M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | ($12.00M) | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $6.11M | Dec 13, 2018 |
| FY2013 | Sep 30, 2013 | $7.39M | Dec 13, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $222.60M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $208.12M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $195.92M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $179.31M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $179.46M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $171.09M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $165.37M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $156.14M | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $142.89M | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $128.71M | Dec 6, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.79M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $11.98M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $14.34M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $12.40M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $12.17M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $9.87M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $9.86M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $11.13M | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $13.98M | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $8.51M | Dec 6, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $211.80M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $196.14M | Dec 9, 2025 |
| FY2025 | Sep 30, 2023 | $181.58M | Dec 9, 2025 |
| FY2024 | Sep 30, 2022 | $166.92M | Jun 27, 2025 |
| FY2023 | Sep 30, 2021 | $167.29M | Dec 13, 2023 |
| FY2022 | Sep 30, 2020 | $161.22M | Dec 16, 2022 |
| FY2021 | Sep 30, 2019 | $155.52M | Dec 17, 2021 |
| FY2020 | Sep 30, 2018 | $145.02M | Dec 18, 2020 |
| FY2019 | Sep 30, 2017 | $128.92M | Dec 11, 2019 |
| FY2018 | Sep 30, 2016 | $120.21M | Dec 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $197.75M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $182.09M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $167.53M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $152.86M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $153.23M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $147.43M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $141.90M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $131.70M | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $116.30M | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $107.88M | Dec 6, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $26.59M | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $25.48M | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $17.03M | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $9.58M | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $23.23M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $35.58M | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $10.30M | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $8.01M | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $22.93M | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $18.22M | Dec 6, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $0 | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | $0 | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | $0 | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | $0 | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | $0 | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | $0 | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Dec 11, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Dec 13, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Dec 6, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 1 | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | 1 | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Dec 11, 2019 |
| FY2017 | Sep 30, 2017 | 0 | Dec 6, 2017 |
| FY2017 | Jun 30, 2017 | 0 | Dec 6, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 1 | Dec 9, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 9, 2025 |
| FY2024 | Sep 30, 2023 | 1 | Jun 27, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Dec 13, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 17, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Dec 18, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Dec 11, 2019 |
| FY2017 | Sep 30, 2017 | 0 | Dec 6, 2017 |
| FY2017 | Jun 30, 2017 | 0 | Dec 6, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Sep 30, 2013 | 8.01M | Dec 13, 2013 |
| FY2012 | Sep 30, 2012 | 8.01M | Dec 14, 2012 |
| FY2011 | Sep 30, 2011 | 8.01M | Dec 16, 2011 |
| FY2011 | Sep 30, 2010 | 8.01M | Dec 16, 2011 |